ArticleKidney international reports2025
Frailty Among Patients With ADPKD.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Increased risk of incident and recurrent urinary tract infection in autosomal dominant polycystic kidney disease: a contemporary propensity score-matched cohort study.Internal and emergency medicine · 2026Article
- The Weight of Disease, the Loss Within: Rethinking Frailty Assessment in ADPKD.Kidney international reports · 2026Article
- Response to the Letter to the Editor Entitled "The Weight of Disease, the Loss Within: Rethinking Frailty Assessment in ADPKD".Kidney international reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is a major inherited cause of end-stage kidney disease (ESKD), associated with various systemic complications. Frailty, a degenerative condition linked to adverse health outcomes, may be influenced by ADPKD and its complications; however, data on this association is limited. This study investigated whether ADPKD is associated with increased risk of incident or worsening frailty. Methods: We conducted a retrospective cohort study, using the National Taiwan University Hospital Integrate Medical Database (2006-2021). Adults with ADPKD or simple kidney cysts (SKCs) were identified. After applying exclusion criteria and 1:4 propensity score (PS) matching, 775 patients with ADPKD and 3100 matched SKC controls were included. Frailty status was assessed using the FRAIL scale. Kaplan-Meier curves and Cox proportional hazards were used to evaluate associations with incident and worsening frailty, adjusting for clinical variables. Competing risk analysis accounting for mortality or ESKD was performed. Results: Over 4.8 years of follow-up, 88 participants (2.3%) developed incident frailty and 810 (20.9%) experienced worsening frailty. ADPKD was not significantly associated with higher risk of incident frailty (hazard ratio [HR]: 1.20, 95% confidence interval [CI]: 0.69-2.08) or worsening frailty (HR: 0.98, 95% CI: 0.82-1.17). Results remained consistent across subgroups stratified by age, kidney function, and baseline frailty, and after accounting for competing mortality or ESKD. Conclusion: In this matched cohort study, ADPKD was not associated with an increased risk of incident or worsening frailty. These findings suggest that ADPKD may not independently drive functional decline beyond its impact on kidney function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.